Subscribe to our Telegram channel for the latest updates on news you need to know.
WASHINGTON, Apr 1 — The Pfizer-BioNTech Covid-19 vaccine has demonstrated 100 per cent efficacy and robust antibody responses in a Phase Three trial in adolescents 12 to 15 years of age, Xinhua news agency quoted the two companies on Wednesday.
